Pharmaceutical and vaccine company BioCina is planning to scale up from laboratory to industrial scale a bioseparation resin technology for the large-scale production of complex medicines made from biopharmaceuticals. Backed by an Australian Economy Accelerator (AEA) grant, Griffith University Institute for Biomedicine and Glycomics Principal Research Leader, Professor Bernd Rehm and his team are leading…
Microbial development and contract manufacturing companies Adelaide’s BioCina and Perth’s NovaCina have announced a strategic partnership to provide integrated drug substance and drug product solutions for the pharmaceutical sector. The two companies are buy-outs from the Pfizer pharmaceutical company and share the same investor – private investment firm Bridgewest Group – and will now collaborate…
GenomeFrontier Theraputics AU has partnered with BioCina for a project to develop products for gene therapy cancer treatments.
Pharmaceutical and vaccine manufacturer BioCina is industry partner in an ambitious research project that aims to develop vaccine candidates to protect against biowarfare threats including Q Fever, tularaemia, and melioidosis. BioCina, the health Security Systems Australia (HSSA) division of defence innovation group DMTC, and academics led by Griffith University, including the Australian Rickettsial Reference Laboratory…
